TB-500 + BPC-157

A two-peptide toolkit for connective tissue and vascular repair research

Technical datasheetLZH-007

Code: Regenerative duo
Half-life: TB-500: hours; BPC-157: short plasma, longer tissue residence
Research route: Subcutaneous / IM (research)
Molecular targets: G-actin (TB-500) · VEGFR2 / NO-pathway / GH-R upregulation (BPC-157)
Discovery / disclosure: TB-500: synthetic Tβ4 active fragment, 1990s; BPC-157: Sikiric lab, Zagreb, 1991
Target purity: ≥ 98%
Recommended storage: −20°C, light protected. 2 to 8°C after reconstitution.

Aliases

Thymosin β4 fragment (1-4 + 17-23) + Body Protection Compound 157

Appearance

White lyophilized powder

Solubility

Both highly water soluble

Sequence

TB-500: Ac-LKKTETQ | BPC-157: GEPPPGKPADDAGLV

Analysts reviewing the HPLC chromatogram for the current batch — FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.

Technician monitoring a stainless steel reactor during scale-up — FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.

Overview

TB-500 is an active fragment of thymosin beta 4. BPC-157 is a stable pentadecapeptide derived from a gastric protective protein.

Both are commonly used as a tool combination in tissue repair research.

Pharmacology and mechanism

TB-500 binds G-actin and supports cell migration and neovascularization. BPC-157 modulates VEGFR2, nitric oxide pathways and tendon fibroblast activity.